Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF

NCT06078436 · tracked via the Priya Life Science South Korea tracker

Sponsor

Min-Seok Kim

Phase

Not applicable

Started

2024-01

Last updated

2024-01-05

Condition(s) studied

Heart Failure With Reduced Ejection FractionCardiogenic Shock

Investigational drug(s) / intervention(s)

Pulmonary artery catheter

Pulmonary artery catheter: Pulmonary artery catheter monitoring or not

Study summary

This study aims to compare the impact of hemodynamic monitoring using pulmonary artery catheter (PAC) on survival and inotropic agent reduction in patients with cardiogenic shock caused by heart failure with reduced ejection fraction (HFrEF). The investigators also intend to compare the difference in long-term survival rates among patients who have recovered from cardiogenic shock due to HFrEF, based on the timing of initiation of beta-blocker treatment.

Eligibility

Sex

ALL

Min age

19 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Adults age 19 and above ( no age limit for elderly ) * Patients with cardiogenic shock requiring intensive care monitoring in ICU * Patients eligible for oral medication administration * Patients who have provided research participation consent through a written informed consent form Exclusion Criteria: * Unwilling or unable to obtain informed consent by the participant or substitute decision maker * Patients with mechanical circulatory support at the time of screening * Patients with acute coronary syndrome * Patients with severe valvular heart disease requiring emergent percutaneous procedures or surgery * Known hypersensitivity to beta-blockers * Patients with a history of bronchospasm or asthma * Patients with bradycardia or second or third-degree atrioventricular block * Patients with sick sinus syndrome, including sinoatrial block * Patients with untreated pheochromocytoma * Patients currently undergoing de-sensitization therapy * Patients who are currently pregnant, postpartum period within 30 days or breast-feeding

Primary outcome measure(s)

30-day all-cause mortality — From date of randomization until the date of death from any cause, assessed up to 30 days
All-cause mortality

Trial sites (1)

Facility	City	Region	Status
Asan Medical Center	Seoul	South Korea	Recruiting

More Min-Seok Kim trials in South Korea

Distal Perfusion Timing, Early or Conservative, to Prevent Limb Ischemia During Peripheral VA-ECMO Recruiting

Other trials for the same condition

Revascularization Versus Medical Treatment in Patients With Ischemic Left Ventricular Dysfunction Recruiting

The Current Status and Clinical OUTcomes of Cardiogenic Shock Patients And the Role of Specialist in Cardiovascular Critical Care Unit Recruiting

Assessing Catecholamine Treatment Initiation Options: Norepinephrine vs Dopamine for Cardiogenic Shock Starting soon

Accelerated vs. Standard Continuous Renal Replacement Therapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator Recruiting

Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06078436 on ClinicalTrials.gov ↗ ← All trials in South Korea